pulmonari
complic
significantli
contribut
treatmentrel
morbid
mortal
allogen
stem
cell
transplant
sct
wherea
infecti
diseas
lung
predomin
previou
year
increas
use
prophylact
antibiot
shift
spectrum
toward
noninfecti
caus
tradit
pulmonari
toxic
observ
rang
recent
studi
report
divers
gener
lower
unfortun
trial
appli
uniform
definit
noninfecti
pulmonari
complic
bestcharacter
earli
onset
lung
injuri
sct
diffus
alveolar
hemorrhag
dah
wherea
bronchiol
obliteran
bo
bronchiol
obliteransorgan
pneumonia
boop
occur
later
post
transplant
period
common
complic
idiopath
pneumonia
syndrom
ip
defin
evid
widespread
alveolar
injuri
absenc
lower
respiratori
tract
may
develop
earli
commonli
later
set
addit
less
frequent
encount
form
pulmonari
toxic
periengraft
respiratori
distress
syndrom
delay
pulmonari
toxic
syndrom
among
variabl
analyz
possibl
influenc
develop
pulmonari
complic
graftversushost
diseas
gvhd
emerg
consist
risk
suggest
role
inflammatori
mediat
alloreact
donor
lymphocyt
howev
experiment
data
yet
abl
show
mechanist
moreov
associ
gvhd
vari
among
differ
type
lung
injuri
wherea
bo
boop
occur
almost
exclus
patient
chronic
gvhd
among
mani
risk
factor
prerequisit
develop
pathogenesi
dah
unclear
usual
diagnos
earli
post
transplant
gvhd
identifi
critic
current
studi
character
spectrum
incid
pulmonari
toxic
larg
cohort
patient
uniformli
treat
cyclophosphamid
total
bodi
irradi
tbi
follow
partial
tcelldeplet
sct
analyz
relationship
lung
injuri
gvhd
pulmonari
complic
review
computer
databas
consecut
patient
receiv
either
allogen
bone
marrow
allobmt
peripher
blood
sct
allopbsct
januari
juli
institut
control
subject
select
databas
control
match
pulmonari
case
sex
underli
diagnosi
age
type
transplant
sib
matchedunrel
donor
mud
bmt
pbsct
cytomegaloviru
cmv
serostatu
best
possibl
extent
patient
underw
previou
allogen
autolog
sct
exclud
analysi
patient
treat
accord
clinic
protocol
approv
local
investig
review
board
inform
consent
obtain
patient
condit
myeloabl
regimen
consist
cyclophosphamid
mgkgday
day
follow
tbi
cgyday
day
partial
shield
lung
total
lung
dose
cgi
graft
partial
consist
cellskg
infus
second
tbi
fraction
day
dose
measur
pbsct
median
dose
antithymocyt
globulin
thymoglobulin
sangstat
amstelveen
netherland
given
mud
patient
cyclophosphamid
infus
total
dose
mgkg
april
mgkg
thereaft
post
transplant
immunosuppress
consist
cyclosporin
discontinu
within
month
transplant
activ
gvhd
present
gvhd
diagnos
accord
seattl
treat
mgkgday
prednisolon
resumpt
full
dose
cyclosporin
applic
donor
lymphocyt
infus
administ
case
residu
diseas
relaps
dose
cellskg
eight
patient
pulmonari
diseas
control
infect
prevent
consist
ciprofloxacin
fluconazol
plu
amphotericin
b
granulocyt
count
exceed
cephalothin
given
day
day
furthermor
cotrimoxazol
val
acyclovir
given
oral
day
month
post
transplant
longer
case
activ
gvhd
dose
mg
bid
respect
cmvseroposit
patientdonor
combin
monitor
twice
week
first
day
post
transplant
april
cmv
monitor
base
antigenemia
sinc
cmv
viral
load
determin
cmv
dna
pcr
techniqu
preemptiv
treatment
ganciclovir
start
test
becam
posit
establish
etiolog
pulmonari
diseas
review
two
author
ch
lfv
basi
clinic
radiolog
microbiolog
histolog
find
pneumonia
classifi
infecti
base
pathogen
report
accord
distinguish
featur
describ
noninfecti
complic
defin
bo
absenc
fever
pulmonari
infiltr
presenc
airway
obstruct
boop
fever
patchi
pulmonari
consolid
typic
histolog
dah
diffus
pulmonari
infiltr
progress
bloodier
aliquot
lavag
return
andor
hemosiderinladen
macrophag
bronchoscopi
ip
evid
widespread
alveolar
injuri
absenc
lower
respiratori
tract
uncompl
upper
airway
infect
exacerb
chronic
obstruct
pulmonari
diseas
exclud
analysi
baselin
pulmonari
function
test
obtain
patient
post
transplant
pulmonari
function
test
perform
patient
present
pulmonari
complaint
imag
studi
ctscan
andor
xray
chest
well
cultur
viral
screen
sputum
blood
perform
patient
present
fever
cough
dyspnea
andor
pulmonari
infiltr
post
transplant
octob
march
routin
nasopharyng
throat
swab
analyz
pcr
detect
respiratori
virus
adenoviru
parainfluenza
viru
rs
viru
influenza
viru
rhinoviru
coronaviru
enteroviru
describ
treatment
initi
broadspectrum
antibiot
given
intraven
case
neutropenia
amphotericin
ad
patient
remain
febril
fiberopt
bronchoscopi
sampl
bronchoalveolar
lavag
bal
fluid
perform
whenev
possibl
patient
respond
empir
antibiot
therapi
histolog
biopsi
taken
accord
clinic
situat
condit
patient
differ
group
compar
logist
regress
account
match
use
control
select
model
includ
variabl
interest
well
covari
consid
priori
potenti
confound
sex
underli
diagnosi
age
type
transplant
cmvserostatu
preval
chronic
gvhd
could
calcul
patient
surviv
day
differ
patient
infecti
noninfecti
caus
lung
injuri
compar
pearson
test
overal
surviv
estim
cox
proport
hazard
analysi
odd
ratio
or
confid
interv
ci
calcul
test
twosid
pvalu
consid
statist
signific
calcul
perform
use
spss
inc
chicago
il
usa
patient
review
studi
develop
pulmonari
complic
allogen
sct
patient
transplant
characterist
group
control
subject
shown
tabl
minor
pulmonari
diseas
repres
infecti
caus
patient
four
case
clinic
cours
fulli
compat
infecti
pneumonia
pathogen
could
determin
forti
patient
develop
noninfecti
complic
subclassifi
bo
patient
boop
two
patient
dah
three
patient
ip
patient
bronchoscopi
bal
perform
patient
classifi
ip
yield
neg
cultur
result
mix
etiolog
establish
two
patient
tabl
pulmonari
complic
diagnos
median
week
transplant
rang
week
median
time
onset
differ
patient
infecti
problem
ip
week
respect
wherea
bo
occur
later
stage
median
week
tabl
show
preval
sever
acut
chronic
gvhd
group
pulmonari
patient
control
consequ
tcelldeplet
allograft
number
grade
iii
iv
gvhd
small
overal
incid
acut
gvhd
ii
significantli
higher
among
patient
pulmonari
complic
group
differ
seen
patient
infecti
noninfecti
caus
lung
injuri
preval
chronic
gvhd
differ
significantli
group
although
tendenc
toward
higher
overal
incid
pulmonari
patient
limit
extens
chronic
gvhd
or
acut
chronic
gvhd
ci
ci
respect
none
variabl
assess
logist
regress
model
could
identifi
correl
factor
howev
cmv
reactiv
significantli
frequent
among
patient
pulmonari
complic
ci
patient
pulmonari
complic
occur
period
viral
upper
lower
respiratori
tract
infect
monitor
viral
airway
infect
detect
patient
upper
respiratori
tract
infect
preced
subsequ
lung
injuri
bo
one
patient
overal
pulmonari
patient
aliv
time
analysi
fortyseven
patient
die
mainli
patient
owe
pulmonari
complic
control
subject
aliv
die
median
surviv
week
rang
week
pulmonari
patient
week
rang
week
control
subject
median
followup
week
respect
surviv
similar
patient
infecti
caus
ip
median
week
rang
week
respect
wherea
patient
bo
better
outcom
median
week
rang
week
data
confirm
partial
tcell
deplet
result
low
incid
gvhd
pulmonari
complic
contrast
result
recent
studi
without
tcell
studi
pulmonari
complic
significantli
associ
acut
gvhd
ii
cmv
reactiv
increas
risk
pulmonari
problem
found
among
patient
chronic
gvhd
statist
signific
probabl
due
use
partial
tcelldeplet
graft
result
much
lower
incid
chronic
ghvd
report
two
studi
demonstr
relationship
chronic
gvhd
late
noninfecti
pulmonari
moreov
subset
patient
present
could
identifi
viral
respiratori
tract
infect
risk
factor
progress
lung
injuri
suggest
noninfecti
pulmonari
complic
sct
associ
gvhd
initi
came
observ
incid
lower
autolog
allogen
line
find
tcell
deplet
lower
incid
gvhd
lung
associ
chronic
gvhd
bo
well
accept
mainli
basi
consist
epidemiolog
howev
experiment
epidemiolog
data
role
gvhd
develop
ip
contradictori
underlin
lack
clear
mechanist
basi
epitheli
cell
apoptosi
classic
gvhd
histopatholog
find
consist
find
howev
cook
et
point
epitheli
cell
apoptosi
requir
gvhd
patholog
lung
biopsi
may
difficult
interpret
nonspecif
chang
occur
exampl
mechan
ventil
suboptim
biopsi
specimen
owe
risk
associ
procedur
experiment
model
identifi
role
alloreact
cell
well
inflammatori
mediat
antigenpres
cell
pathogenesi
ip
recent
specif
express
chemokin
ligand
rant
donor
cell
contribut
leukocyt
recruit
interestingli
observ
murin
model
tcell
deplet
allograft
significantli
reduc
elimin
pulmonari
matur
donor
cell
significantli
increas
bal
fluid
mice
receiv
allogen
cell
compar
syngen
control
even
absenc
gvhd
give
weight
theori
host
reactiv
donor
cell
play
central
role
rather
gvhd
per
se
addit
allogen
studi
use
low
tcell
dose
patient
die
ip
none
develop
signific
yet
novel
insight
come
grow
experi
nonmyeloabl
sct
recent
shown
group
patient
rate
noninfecti
pulmonari
toxic
low
nonmyeloabl
condit
without
irradi
infecti
pneumonia
occur
nine
patient
two
patient
develop
ip
case
dah
bo
overal
incid
acut
gvhd
grade
iii
grade
iiiiv
extens
chronic
gvhd
respect
anoth
report
demonstr
reducedintens
condit
decreas
incid
bo
wherea
chronic
gvhd
risk
moreov
nonmyeloabl
patient
experienc
significantli
lower
rate
lung
function
declin
sct
myeloabl
intens
condit
regimen
convent
versu
nonmyeloabl
occurr
sever
acut
gvhd
grade
prognost
develop
ip
multipl
regress
larg
cohort
patient
pulmonari
complic
control
compar
respect
wellknown
risk
factor
lung
injuri
acut
gvhd
ii
significantli
relat
pulmonari
toxic
differ
incid
acut
gvhd
patient
infecti
noninfecti
pulmonari
complic
could
identifi
viral
respiratori
tract
infect
risk
factor
progress
lung
injuri
interestingli
note
associ
pulmonari
complic
cmv
reactiv
among
previous
report
risk
factor
therefor
role
cmv
reactiv
effect
prophylaxi
preemptiv
therapi
develop
pulmonari
complic
deserv
evalu
studi
sever
limit
owe
retrospect
natur
studi
might
miss
singl
patient
pulmonari
problem
spite
detail
computer
databas
extens
chart
review
moreov
rule
undetermin
relev
differ
case
control
match
nevertheless
focu
assess
influenc
gvhd
develop
pulmonari
diseas
data
illustr
incid
pulmonari
complic
low
partial
tcelldeplet
sct
demonstr
clear
associ
acut
gvhd
still
improv
poor
outcom
pulmonari
complic
utmost
import
